help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 7, 2004
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1532
A more recent version of this article appeared on March 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/3/1798    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaytan, F.
Right arrow Articles by Tena-Sempere, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaytan, F.
Right arrow Articles by Tena-Sempere, M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Ovarian Cancer

Submitted on August 3, 2004
Accepted on November 23, 2004

Expression of Growth Hormone Secretagogue Receptor Type 1a, the Functional Ghrelin Receptor, in Human Ovarian Surface Epithelium, Mullerian Duct Derivatives and Ovarian Tumors*

F. Gaytan, C. Morales, M. L. Barreiro, P. Jeffery, L. K. Chopin, A. C. Herington, F. F. Casanueva, E. Aguilar, C. Dieguez, and M. Tena-Sempere*

Departments of Cell Biology, Physiology and Immunology (F.G., M.L.B., E.A., M.T.-S.), and Pathology (C.M.), University of Córdoba, 14004 Córdoba, Spain; Departments of Physiology (C.D.) and Medicine (F.F.C.), University of Santiago de Compostela, 15705 Santiago de Compostela, Spain; and School of Life Sciences, Cluster for Molecular Biotechnology (P.J., L.K.C., A.C.H.), Queensland University of Technology, Brisbane, Queensland, Australia

* To whom correspondence should be addressed. E-mail: fi1tesem{at}uco.es.

Ghrelin, the endogenous ligand of the growth hormone secretagogue receptor (GHS-R), is a newly identified, ubiquitously expressed molecule which has been involved in a wide array of endocrine and non-endocrine functions, including cell proliferation. In this context, our group has recently reported the expression of ghrelin and its functional receptor, the GHS-R type 1a, in the human ovary and testis, as well as in several testicular tumors. Ovarian malignancies, however, remain unexplored. Notably, a vast majority of ovarian tumors derive from the surface epithelium, which originates from the celomic epithelium. Considering the proven expression of ghrelin in the human ovary, and its reported effects in the proliferative activity of different cancer cell lines, we aimed at evaluating whether the ovarian surface epithelium, as well as related reproductive structures and tumors, are potential targets of ghrelin. To this end, expression of GHS-R1a was analyzed by immuno-histochemistry in a panel of normal, metaplastic and neoplastic tissues. Uniform GHS-R1a immunostaining was detected throughout the ovarian surface epithelium. Likewise, ciliated cells within the Fallopian tube epithelium showed strong GHS-R1a expression. In contrast, other celomic derivatives, such as endometrium and endocervix, were negative for GHS-R1a immunoreactivity. In keeping with data from normal tissues, inclusion cysts from the surface epithelium expressed GHS-R1a. Similarly, benign serous tumors resembling Fallopian tube epithelium were also positive, whereas serous cystadenocarcinomas showed GHS-R1a expression only in highly differentiated specimens. In contrast, other neoplasms, such as mucinous cystadenomas and cystadenocarcinomas, endometrioid tumors, clear cell carcinomas and Brenner tumors, did not express GHS-R1a. In conclusion, our results demonstrate that the ovarian surface epithelium and related tumors are potential targets for systemic or locally produced ghrelin, as they express the functional type 1a GHS-R. Considering the relevant role of the ovarian surface epithelium in key physiological events (such as ovulation) and neoplastic transformation of the ovary, the potential actions of ghrelin in those phenomena merit further investigation.


Key words: Ghrelin • growth hormone secretagogue (GHS) • GHS-receptor • Ovarian Surface Epithelium (OSE) • Mullerian Duct • Tumor • Ovary • Human




This article has been cited by other articles:


Home page
ReproductionHome page
M. C Garcia, M. Lopez, C. V Alvarez, F. Casanueva, M. Tena-Sempere, and C. Dieguez
Role of ghrelin in reproduction
Reproduction, March 1, 2007; 133(3): 531 - 540.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society